Tumor Microenvironment (TME) Component Targeting based Antibody Production Services
Background Service Workflow Type Highlights Published Data FAQs Contact
Are you currently facing limited efficacy of conventional treatments or challenges in overcoming drug resistance due to the complex tumor microenvironment? Our tumor microenvironment (TME) component targeting based antibody production services help you accelerate therapeutic discovery and develop highly specific and effective antibody-based therapies through advanced antibody engineering, high-throughput screening, and comprehensive TME-focused validation.
Introduction
TME is a complex and dynamic ecosystem that plays a pivotal role in cancer progression, metastasis, and, critically, therapeutic resistance. Comprising diverse cellular and non-cellular components, the TME actively shields tumors from conventional treatments and immune surveillance.
Fig.1 Targeting the TME as a feasible therapeutic strategy.1,3
TME Component Targeting based Antibody Production Services at Creative Biolabs
Creative Biolabs' services are dedicated to developing highly specific antibody-based therapies that precisely target these key TME components, such as cancer-associated fibroblasts (CAFs), immune cells, and the extracellular matrix (ECM). This innovative approach aims to overcome inherent resistance mechanisms and significantly enhance overall therapeutic efficacy.
We offer a comprehensive suite of services designed to develop cutting-edge antibody-based therapies that precisely target the TME. Our solutions focus on disrupting the TME's pro-tumorigenic functions, enhancing immune responses, and overcoming drug resistance, leading to more effective cancer treatments. We provide the expertise and platforms to develop highly specific antibodies, antibody-drug conjugates (ADCs), and immunocytokines tailored to your project's unique needs.
How It Works
Our highly optimized and streamlined workflow is meticulously designed to guarantee a clear, professional, and seamless progression from the initial conceptualization of therapeutic ideas all the way through to the rigorous validation of promising therapeutic candidates.
Types of our TME Component Targeting based Antibody Production Services
Creative Biolabs offers a diverse range of TME component targeting based antibody production services, each tailored to address specific aspects of the complex tumor microenvironment.
Stroma Targeting Antibody Production
This service focuses on developing antibodies against crucial components of the tumor stroma, aiming to dismantle the supportive and protective extracellular matrix and cellular networks. We target key elements such as CAFs, which are known to promote tumor growth, angiogenesis, drug resistance, and immunosuppression. Additionally, we target components of the ECM, including specific fibronectin domains, matrix metalloproteinases, and lysyl oxidase enzymes. By modulating these targets, our antibodies aim to reduce tumor stiffness, improve drug penetration, and inhibit tumor invasion.
Vascular Targeting Antibody Production
This specialized service focuses on developing antibodies that specifically target the abnormal and often leaky vasculature within tumors. The goal is to inhibit tumor angiogenesis (the formation of new blood vessels), normalize existing tumor blood vessels, and enhance the delivery of therapeutic agents directly to the tumor core. Key targets include vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), crucial drivers of new vessel formation. Furthermore, we explore targeting pericytes and other supporting cells of the tumor vasculature that contribute to vessel stability and permeability, aiming to deprive the tumor of essential nutrients and oxygen.
Benefits for You
- Integrated Antibody Development Pipeline: We provide one - stop service covering the entire antibody development lifecycle - from target identification, discovery, engineering, payload conjugation (for ADCs), immunocytokine fusion, to in vitro/in vivo preclinical validation, ensuring efficiency and consistency.
- Optimized Expression & Production: We develop efficient upstream/downstream processes for antibody production. Optimize gene expression and culture conditions to maximize yield and quality.
- Scalable Bioreactor Capabilities: With advanced bioreactors, we enable scalable production from lab - scale to large - scale, supporting preclinical/early clinical studies of TME - targeted antibodies.
- Rigorous Quality Assurance & Control: Quality is key. Implement QbD, PAT, strict aseptic procedures, and high - standard QC tools to ensure product consistency and purity.
- Compliant Production: For high - standard projects, offercompliant production, facilitating clinical translation of TME - targeted therapeutics.
- Guaranteed Stability & Characterization:Ensure stability of cell banks and antibodies. Thoroughly characterize, with strain origin docs assessed by quality assurance for reliable materials.
- Customized Solutions: Acknowledge unique project needs. Offer customized services for TME - targeted antibody development—novel formats, conjugation, preclinical models. Experts design solutions aligning with scientific goals.
Case Study
Summary: This study investigates L19-IL2, an antibody-cytokine fusion protein that targets a specific fibronectin variant in pancreatic ductal adenocarcinoma. Using syngeneic mouse models and 3D tumor spheroids, it shows that L19-IL2 has dose-dependent anti-tumor effects, boosting the infiltration of T-lymphocytes and their ability to kill cancer cells by increasing substances like granzymes, perforins, and IL-2 receptors. When combined with a chemotherapy regimen, it reduces tumor growth and extends survival more effectively than either treatment alone.
Fig.2 Real-time analysis technology was used to detect the real-time expression of antibodies in tumor sphere model.2,3
FAQs
How do TME-targeted antibodies differ from traditional cancer therapies?
Traditional cancer therapies primarily focus on directly killing cancer cells, which can often lead to the development of resistance due to the dynamic nature of tumor cells. TME-targeted antibodies, like those developed by Creative Biolabs, take a different approach. They focus on disrupting the supportive tumor microenvironment, which is crucial for tumor growth, survival, and drug resistance. By targeting components like CAFs, immune suppressors, or the ECM, our antibodies can dismantle the tumor's protective shield, making it more vulnerable to treatment and enhancing the efficacy of existing therapies.
What types of TME components can your services target?
Our services are highly versatile and can target a broad spectrum of TME components. This includes specific proteins on cancer-associated fibroblasts (e.g., FAP), various immune cell populations (e.g., specific markers on TAMs or Tregs), extracellular matrix elements and factors involved in tumor angiogenesis, hypoxia, and metabolism. We encourage a detailed discussion of your specific research objectives so we can identify and target the most impactful TME components for your project.
Can your TME-targeted antibodies be combined with other treatments?
Absolutely. One of the most significant advantages of TME-targeted therapies is their strong synergistic potential. Our antibody-based solutions are meticulously designed to be highly compatible with conventional treatments such as chemotherapy and radiotherapy, as well as other immunotherapies. By effectively modulating the TME, our antibodies can facilitate better drug penetration, alleviate immunosuppression, and ultimately lead to significantly improved overall treatment outcomes when used in combination.
Why Choose Us?
Creative Biolabs stands at the forefront of TME-targeted antibody development, offering unparalleled advantages that set us apart. With over 20 years of experience in biology and exceptional scientific knowledge, our team is dedicated to providing high-end solutions for your therapeutic projects. We leverage an integrated platform and cutting-edge technologies to ensure the development of highly specific and effective TME-targeted agents. Our proven track record in overcoming complex biological challenges underscores our commitment to your success.
Customer Reviews:
"Using Creative Biolabs' TME component targeting based antibody production services in our research has significantly improved the in vivo efficacy of our lead therapeutic candidate. Their precise antibody engineering led to superior tumor targeting and reduced systemic toxicity compared to our previous efforts. The detailed characterization data provided invaluable insights for our next steps." - Dr. Jn Sh, Principal Investigator, 2024.
"Creative Biolabs' expertise in TME modulation was critical in addressing the drug resistance we faced in our pancreatic cancer models. Their immunocytokine development platform allowed us to transform an immunosuppressive tumor into an immunologically 'hot' one, enabling synergistic effects with chemotherapy. This breakthrough fundamentally changed our therapeutic strategy." - Dr. Aa Mr, Head of Oncology Research, 2023.
How to Contact Us
Ready to revolutionize your cancer therapy pipeline? Contact our team today to discuss your specific project needs and explore how Creative Biolabs can assist you in developing groundbreaking TME-targeted antibody solutions.
Let our team support you—contact us for info and to talk over your project.
References
- Bilotta, Maria Teresa et al. "Managing the TME to improve the efficacy of cancer therapy." Frontiers in immunology vol. 13 954992. 20 Oct. 2022. DOI: https://doi.org/10.3389/fimmu.2022.954992
- Carbone, Carmine et al. "Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice." Journal of experimental & clinical cancer research : CR vol. 44,1 7. 7 Jan. 2025. DOI: https://doi.org/10.1186/s13046-024-03238-x
- Distributed under Open Access License CC BY 4.0, without modification.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
